|
KMID : 0378019870300080081
|
|
New Medical Journal
1987 Volume.30 No. 8 p.81 ~ p.85
|
|
|
Evaluation of the´use of Ceftriaxone (Rocephin^(®)) in the Orthopedic field
|
|
|
|
|
Abstract
|
|
|
Ceftriaxone (Rocephin®) is a new semi-synthetic broad spectrum, third generation cephalosporin whi h
is manufactured by,the Roche Pharm. Co. It has a high degree of stability in the presence of beta-lactamas,both penicillinases and cephalosporinases and gram-negative and gram- positive organisms, and its half-life ranges from 5.8 to 8.7 hours.
A clinical study was performed using this drug for the treatment of sepsis in 10 patients, for soft tiss e infection in 10 patients and for prophylactic use in 20 patients.
Each patients for treatment and prophylaxis was given 2.0 and 1.0g of Ceftriakone once a day is the intravenous route respectively.
Ten sepsis and osteomyelitis patients were treated for an average of ten days, and eight of them showed improvement and no complications were seen.
Ten soft tissue infection patients were treated, and eight of them showed improvement. The judgment of improvement was based on the absence of clinical symptoms and signs of infection and no gro of organisms from would culture.
Twenty patients who were given Ceftriaxone for the purpose of prophylaxis showed no post-operati - infection.
We concluded that Ceftriaxone is a safe and effective drug in the orthopedic field and it may also be used at out-patient Dept. to shorten the hospital days and reduce the cost.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|